MedTrace Logo

Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients

NCT01738646 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2017-03-06

Study results available
· View outcomes & findings →

Summary

It has been shown that bevacizumab has significant anti-tumor activity in patients with recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against malignant glioma and can enhance the action of both chemotherapy and anti-angiogenics. Patients will be treated with a combination of bevacizumab and vorinostat.

Conditions

  • Recurrent Glioblastoma Multiforme
  • Malignant Glioma
  • Adult Brain Tumor

Interventions

DRUG

Vorinostat

DRUG

Bevacizumab

Sponsors & Collaborators

Principal Investigators

  • Katherine Peters, MD, PhD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-12-31
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01738646 on ClinicalTrials.gov